Telling a patient that they will have to stop driving can be difficult, so it is essential to be sure of the facts on the law regulating driving and chronic disease. When asked what they know about chronic disease and stopping driving, many people may know that epilepsy is an issue, and may mention diabetes. But are driving restrictions for one year, or is it three years? Do they affect only patients with diabetes on insulin, and are some regulations only for heavy goods vehicle (HGV) drivers? In this article, we give you the information to answer these questions.
Electrocardiography as a prognostic tool for identifying the development of heart failure in patients with β-thalassaemia: a retrospective cohort study
Maximising healthcare benefits for individual patients and society as a whole
Where are we now with rosiglitazone? A comment from GlaxoSmithKline
A survey of GPs’ views on clinical and cost issues in prescribing statins
Statin therapy for secondary prevention of coronary heart disease: an update
Optimising use of statins in clinical practice: how to achieve the best clinical outcomes for every patient
“You Will Need to Stop Driving.” Chronic Disease, Driving and the Law
The Metabolic Syndrome: Pie in the Sky or Major New Disease?
The metabolic syndrome is a bit like smoothie makers. Everyone’s heard of them, many people seem to have them, but no-one is quite sure what to do with them. So let’s have a look at how the metabolic syndrome came to enter our vocabulary, what it really means and whether it is something that could help us to look after our patients better or just another cumbersome tool that produces a lot of heat but no light.
Procoralan (Ivabradine): A New Treatment Option for Angina
Angina is on the increase as people live longer. It is the most common symptom of ischaemic heart disease and occurs when the arteries are no longer able to supply the heart with enough blood to meet its demands. Treatment aims to restore the balance between oxygen supply and demand, to relieve the pain as quickly as possible and prevent further angina attacks, to treat the risk factors, limit the progression of coronary artery disease and reduce the risk of a heart attack. Procoralan (ivabradine) works by specifically inhibiting the If or ‘funny’ channel in the sinoatrial node of the heart (also known as the cardiac pacemaker) to reduce the resting heart rate, matching the efficacy of beta-blockers without their side-effects.
Neurolinguistic Programming: Getting to the Heart of Communication
Imagine what it would be like if you could communicate effectively with every person you meet. What would it be like to know that any messages you want to put across to your patients mean the same to them when they hear them as they mean to you? A few basic pointers in neurolinguistic programming (NLP) may help to improve how clearly you communicate with others. In this article we will look at linguistics, or the use of language, as one part of NLP and a key indicator of how people make sense of, and interpret, the world.
Using troponins to assess cardiac damage: Getting to the heart of the matter
Troponins are now measured routinely in patients with acute chest pain in most hospitals in the UK. Studies have confirmed that they represent a marker of risk for subsequent cardiac events in most patients. In this article we explore what troponins are, why they may increase in acute coronary syndromes, how they are measured and how likely they are to be used in the future.
